首页> 外文期刊>Critical care : >A single preoperative FGF23 measurement is a strong predictor of outcome in patients undergoing elective cardiac surgery: a prospective observational study
【24h】

A single preoperative FGF23 measurement is a strong predictor of outcome in patients undergoing elective cardiac surgery: a prospective observational study

机译:术前单项FGF23的测量可强烈预测择期心脏手术患者的预后:一项前瞻性观察研究

获取原文
           

摘要

IntroductionSeveral scoring systems have been developed to predict postoperative mortality and complications in patients undergoing cardiac surgery. However, these computer-based calculations are time- and cost-intensive. A simple but highly predictive test for postoperative risk would be of clinical benefit with respect to increasingly scarce hospital resources. We therefore assessed the predictive power of fibroblast growth factor 23 (FGF23) measurement compared with an established scoring system.MethodsWe conducted a prospective interdisciplinary observational study at the Saarland University Medical Centre that included 859 patients undergoing elective cardiac surgery between January 2010 and March 2011 with a median follow-up after discharge of 822?days. We compared a single preoperative measurement of FGF23 as a prognostic tool with the 18 parameters comprising EuroSCORE II with respect to postoperative mortality, acute kidney injury, non-occlusive mesenteric ischemia, clinical course and long-term outcome.ResultsPreoperative FGF23 levels were highly predictive of postoperative outcome and complications. The predictive value of FGF23 for mortality in the receiver operating characteristic curve was greater than the EuroSCORE II (area under the curve: 0.800 versus 0.725). Moreover, preoperative FGF23 independently predicted postoperative acute kidney injury and non-occlusive mesenteric ischemia comparably to the EuroSCORE II. Finally, FGF23 was found to be an independent predictor of clinical course parameters, including duration of surgery, ventilation time and length of stay.ConclusionsIn patients undergoing elective cardiac surgery, a simple preoperative FGF23 measurement is a powerful indicator of surgical mortality, postoperative complications and long-term outcome. Its utility compares to the widely used EuroSCORE II.Electronic supplementary materialThe online version of this article (doi:10.1186/s13054-015-0925-6) contains supplementary material, which is available to authorized users.
机译:简介已经开发了几种评分系统来预测心脏手术患者的术后死亡率和并发症。但是,这些基于计算机的计算需要大量时间和成本。相对于医院资源的日益稀缺,对术后风险进行简单但具有高度预测性的测试将具有临床益处。因此,我们与已建立的评分系统相比,评估了成纤维细胞生长因子23(FGF23)测量的预测能力。方法我们在萨尔大学医学中心进行了一项前瞻性的跨学科观察性研究,其中包括859例在2010年1月至2011年3月期间接受择期心脏手术的患者。出院后822天进行中位随访。我们比较了FGF23作为一种预后工具的术前测量结果与包括EuroSCORE II在内的18个参数在术后死亡率,急性肾损伤,非阻塞性​​肠系膜缺血,临床病程和长期预后方面的差异。术后结果和并发症。受体工作特性曲线中FGF23对死亡率的预测值大于EuroSCORE II(曲线下面积:0.800对0.725)。此外,与EuroSCORE II相比,术前FGF23独立预测术后急性肾损伤和非阻塞性肠系膜缺血。最后,发现FGF23是临床过程参数的独立预测指标,包括手术时间,通气时间和住院时间。结论在进行择期心脏手术的患者中,简单的术前FGF23测量是手术死亡率,术后并发症和并发症的有力指标。长期结果。与广泛使用的EuroSCORE II相比,它的实用性。电子补充材料本文的在线版本(doi:10.1186 / s13054-015-0925-6)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号